TransCelerate: a global collaboration across biopharmaceutical R&D to accelerate and simplify new medicines development

As the economic pressures increase on healthcare systems around the world due to aging populations, chronicdiseases, expanding patient populations in emerging markets and advances in medical technology, it is crucial that wefocus on developing and delivering innovative and quality medicines with true medical value to patients around theworld in a more collaborative, quality-focused and cost-effective manner.An important component to this mission across the biopharmaceutical industry is identifying and solving common issues that compromise the success of a clinical development program – the shared pathway to safer and more clinicallymeaningful medicines. However, subject recruitment challenges, data collection and follow-up issues, identification ofhigh-quality trial sites, and lack of successfully achieving study timelines continue to stress clinical trial operationsteams across companies. Although there has been progressing across this range of roadblocks by individual companies,the underlying economics continue to threaten the research and development (R&D) business model.Failure to solve these key issues will affect all parties involved in the clinical trial enterprise: patients, clinical investigators, health authorities, academia, tax-payers and the sponsor companies. The question remains whether a deep andbroad collaborative effort that stretches across the clinical development arena—one that is charged with a common goalof improving quality, enhancing the investigator and patient experience, reducing costs and sharing data—can be acatalyst for success. With encouraging signs already realised, the operation of TransCelerate BioPharma Inc., anon-profit organisation created to improve the health of people around the world by accelerating and enhancing theR&D of innovative new therapies will test this premise.